Japan Approves 3rd Drug for COVID-19 Treatment

Society Lifestyle Politics

Tokyo, April 24 (Jiji Press)--Japan's health ministry has approved the use of baricitinib, a rheumatoid drug, for treating COVID-19 patients, making it the third drug against the coronavirus disease in the country after remdesivir and dexamethasone.

Baricitinib, sold under the brand name Olumiant, is currently administered to patients with rheumatoid arthritis or atopy. COVID-19 patients with moderate to severe symptoms will be given one dose per day of the drug.

In a clinical test, the use of baricitinib, together with remdesivir, has led to faster recovery of COVID-19 patients and lowered death rates among them.

Eli Lilly Japan K.K. applied for approval of baricitinib in December, after the drug was approved for emergency use in the United States in November.


[Copyright The Jiji Press, Ltd.]

Jiji Press